Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Post Traumatic Stress Disorder Market

ID: MRFR/HC/6904-HCR
100 Pages
Nidhi Mandole
Last Updated: May 15, 2026
์™ธ์ƒํ›„ ์ŠคํŠธ๋ ˆ์Šค ์žฅ์•  ์‹œ์žฅ ์กฐ์‚ฌ ๋ณด๊ณ ์„œ ์ •๋ณด: ์น˜๋ฃŒ๋ณ„(ํ”„๋ผ์กฐ์‹ , ํ•ญ๋ถˆ์•ˆ์ œ, ์ •์‹  ์š”๋ฒ•, ์•ฝ๋ฌผ ์น˜๋ฃŒ ๋“ฑ), ์ตœ์ข… ์‚ฌ์šฉ์ž๋ณ„(์™ธ๋ž˜ ์ˆ˜์ˆ  ์„ผํ„ฐ, ๋ณ‘์› ๋ฐ ์ง„๋ฃŒ์†Œ)๋ณ„, ์ง€์—ญ๋ณ„(๋ถ๋ฏธ, ์œ ๋Ÿฝ, ์•„์‹œ์•„ ํƒœํ‰์–‘ ๋ฐ ๊ธฐํƒ€ ๊ตญ๊ฐ€) โ€“ 2032๋…„๊นŒ์ง€ ์‹œ์žฅ ์˜ˆ์ธก
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

  1. 2.1 ์ •์˜
    1. 2.2 ์—ฐ๊ตฌ ๋ฒ”์œ„
      1. 2.2.1 ์—ฐ๊ตฌ ๋ชฉํ‘œ
      2. 2.2.2 ๊ฐ€์ •
      3. 2.2.3 ํ•œ๊ณ„
    2. 3.1 ์„œ๋ก 
    3. 3.2 1์ฐจ ์—ฐ๊ตฌ
    4. 3.3 2์ฐจ ์—ฐ๊ตฌ
    5. 3.4 ์‹œ์žฅ ๊ทœ๋ชจ ์ถ”์ •
    6. 4.1 ๋™์ธ
    7. 4.2 ์ œ์•ฝ
    8. 4.3 ๊ธฐํšŒ
    9. 4.4 ๊ณผ์ œ
    10. 5.1 ํฌํ„ฐ์˜ 5๊ฐ€์ง€ ํž˜ ๋ถ„์„
      1. 5.1.1 ๊ณต๊ธ‰์—…์ฒด์˜ ํ˜‘์ƒ๋ ฅ
      2. 5.1.2 ๊ณต๊ธ‰์—…์ฒด์˜ ํ˜‘์ƒ๋ ฅ ๊ตฌ๋งค์ž
      3. 5.1.3 ์‹ ๊ทœ ์ง„์ž…์ž์˜ ์œ„ํ˜‘
      4. 5.1.4 ๋Œ€์ฒด์žฌ์˜ ์œ„ํ˜‘
      5. 5.1.5 ๊ฒฝ์Ÿ์˜ ๊ฐ•๋„
    11. 5.2 ๊ฐ€์น˜ ์‚ฌ์Šฌ ๋ถ„์„
    12. 6.1 ์„œ๋ก 
    13. 6.2 ์‹ฌ๋ฆฌ ์น˜๋ฃŒ
      1. 6.2.1 ์ธ์ง€ ์น˜๋ฃŒ
      2. 6.2.2 ๋…ธ์ถœ ์น˜๋ฃŒ
      3. 6.2.3 ์•ˆ๊ตฌ ์šด๋™ ๋ฏผ๊ฐ ์†Œ๊ฑฐ ๋ฐ ์žฌ์ฒ˜๋ฆฌ(EMDR)
    14. 6.3 ์•ฝ๋ฌผ
      1. 6.3.1 ํ•ญ์šฐ์šธ์ œ
        1. 6.3.1.1 ํŒŒ๋ก์„ธํ‹ด
        2. 6.3.1.2 ์„ธ๋ฅดํŠธ๋ž„๋ฆฐ
        3. 6.3.1.3 ๋ฏธ๋ฅดํƒ€์žํ•€
        4. 6.3.1.4 ์•„๋ฏธํŠธ๋ฆฝํ‹ธ๋ฆฐ ๋˜๋Š” ํŽ˜๋„ฌ์ง„
      2. 6.3.2 ํ•ญ๋ถˆ์•ˆ์ œ ์•ฝ๋ฌผ
        1. 6.3.2.1 ๋ฒ ํƒ€ ์ฐจ๋‹จ์ œ
        2. 6.3.2.2 ๋ฒค์กฐ๋””์•„์ œํ•€
      3. 6.3.3 ํ”„๋ผ์กฐ์‹ 
    15. 7.1 ์„œ๋ก 
    16. 7.2 ๋ณ‘์› ๋ฐ ์ง„๋ฃŒ์†Œ
    17. 7.3 ์™ธ๋ž˜ ์ˆ˜์ˆ  ์„ผํ„ฐ
    18. 7.4 ๊ธฐํƒ€
    19. 8.1 ์„œ๋ก 
    20. 8.2 ์•„๋ฉ”๋ฆฌ์นด
      1. 8.2.1 ๋ถ๋ฏธ
        1. 8.2.1.1 ๋ฏธ๊ตญ
        2. 8.2.1.2 ์บ๋‚˜๋‹ค
      2. 8.2.2 ๋ผํ‹ด ์•„๋ฉ”๋ฆฌ์นด
    21. 8.3 ์œ ๋Ÿฝ
      1. 8.3.1 ์„œ์œ ๋Ÿฝ
        1. 8.3.1.1 ๋…์ผ
        2. 8.3.1.2 ํ”„๋ž‘์Šค
        3. 8.3.1.3 ์ดํƒˆ๋ฆฌ์•„
        4. 8.3.1.4 ์ŠคํŽ˜์ธ
        5. 8.3.1.5 ์˜๊ตญ
        6. 8.3.1.6 ์„œ์œ ๋Ÿฝ์˜ ๋‚˜๋จธ์ง€ ์ง€์—ญ
      2. 8.3.2 ๋™์œ ๋Ÿฝ
    22. 8.4 ์•„์‹œ์•„ ํƒœํ‰์–‘
      1. 8.4.1 ์ผ๋ณธ
      2. 8.4.2 ์ค‘๊ตญ
      3. 8.4.3 ์ธ๋„
      4. 8.4.4 ํ˜ธ์ฃผ
      5. 8.4.5 ํ•œ๊ตญ
      6. 8.4.6 ์•„์‹œ์•„ ํƒœํ‰์–‘์˜ ๋‚˜๋จธ์ง€ ์ง€์—ญ
    23. 8.5 ์ค‘๋™ ๋ฐ ์•„ํ”„๋ฆฌ์นด
    24. 9.1 ์„œ๋ก 
    25. 9.2 ์‹œ์žฅ ์ ์œ ์œจ ๋ถ„์„
    26. 9.3 ์ฃผ์š” ๊ฐœ๋ฐœ ๋ฐ ์ „๋žต
      1. 9.3.1 ์ฃผ์š” ๊ฐœ๋ฐœ
    27. 10.1 GlaxoSmithKline
      1. 10.1.1 ํšŒ์‚ฌ ๊ฐœ์š”
      2. 10.1.2 ์žฌ๋ฌด ๊ฐœ์š”
      3. 10.1.3 ์ œ๊ณต ์ œํ’ˆ
      4. 10.1.4 ์ฃผ์š” ๊ฐœ๋ฐœ ์‚ฌํ•ญ
      5. 10.1.5 SWOT ๋ถ„์„
      6. 10.1.6 ์ฃผ์š” ์ „๋žต
    28. 10.2 ํ™”์ด์ž
      1. 10.2.1 ํšŒ์‚ฌ ๊ฐœ์š”
      2. 10.2.2 ์žฌ๋ฌด ๊ฐœ์š”
      3. 10.2.3 ์ œ๊ณต ์ œํ’ˆ
      4. 10.2.4 ์ฃผ์š” ๊ฐœ๋ฐœ
      5. 10.2.5 SWOT ๋ถ„์„
      6. 10.2.6 ์ฃผ์š” ์ „๋žต
    29. 10.3 ์—˜๋ฆฌ ๋ฆด๋ฆฌ ์•ค ์ปดํผ๋‹ˆ
      1. 10.3.1 ํšŒ์‚ฌ ๊ฐœ์š”
      2. 10.3.2 ์žฌ๋ฌด ๊ฐœ์š”
      3. 10.3.3 ์ œ๊ณต ์ œํ’ˆ
      4. 10.3.4 ์ฃผ์š” ๊ฐœ๋ฐœ
      5. 10.3.5 SWOT ๋ถ„์„
      6. 10.3.6 ์ฃผ์š” ์ „๋žต
    30. 10.4 H. ๋ฃฌ๋“œ๋ฒก A/S
      1. 10.4.1 ํšŒ์‚ฌ ๊ฐœ์š”
      2. 10.4.2 ์žฌ๋ฌด ๊ฐœ์š”
      3. 10.4.3 ์ œ๊ณต ์ œํ’ˆ
      4. 10.4.4 ์ฃผ์š” ๊ฐœ๋ฐœ
      5. 10.4.5 SWOT ๋ถ„์„
      6. 10.4.5 ํ•ต์‹ฌ ์ „๋žต
    31. 10.5 Azevan Pharmaceuticals
      1. 10.5.1 ํšŒ์‚ฌ ๊ฐœ์š”
      2. 10.5.2 ์žฌ๋ฌด ๊ฐœ์š”
      3. 10.5.3 ์ œ๊ณต ์ œํ’ˆ
      4. 10.5.4 ์ฃผ์š” ๊ฐœ๋ฐœ
      5. 10.5.5 SWOT ๋ถ„์„
      6. 10.5.6 ํ•ต์‹ฌ ์ „๋žต
    32. 10.6 Marinus Pharmaceuticals, Inc.
      1. 10.6.1 ํšŒ์‚ฌ ๊ฐœ์š”
      2. 10.6.2 ์žฌ๋ฌด ๊ฐœ์š”
      3. 10.6.3 ์ œ๊ณต ์ œํ’ˆ
      4. 10.6.4 ์ฃผ์š” ๊ฐœ๋ฐœ
      5. 10.6.5 SWOT ๋ถ„์„
      6. 10.6.6 ํ•ต์‹ฌ ์ „๋žต
    33. 10.7 Tonix Pharmaceuticals Holding Corp.
      1. 10.7.1 ํšŒ์‚ฌ ๊ฐœ์š”
      2. 10.7.2 ์žฌ๋ฌด ๊ฐœ์š”
      3. 10.7.3 ์ œ๊ณต ์ œํ’ˆ
      4. 10.7.4 ํ•ต์‹ฌ ๊ฐœ๋ฐœ
      5. 10.7.5 SWOT ๋ถ„์„
      6. 10.7.6 ํ•ต์‹ฌ ์ „๋žต
    34. 10.8 ๋ฐ”์ด์˜ค๋…ธ๋ฏน์Šค
      1. 10.8.1 ํšŒ์‚ฌ ๊ฐœ์š”
      2. 10.8.2 ์žฌ๋ฌด ๊ฐœ์š”
      3. 10.8.3 ์ œ๊ณต ์ œํ’ˆ
      4. 10.8.4 ํ•ต์‹ฌ ๊ฐœ๋ฐœ
      5. 10.8.5 SWOT ๋ถ„์„
      6. 10.8.6 ํ•ต์‹ฌ ์ „๋žต
    35. 10.9 Greenstone LLC
      1. 10.9.1 ํšŒ์‚ฌ ๊ฐœ์š”
      2. 10.9.2 ์žฌ๋ฌด ๊ฐœ์š”
      3. 10.9.3 ์ œ๊ณต ์ œํ’ˆ
      4. 10.9.4 ํ•ต์‹ฌ ๊ฐœ๋ฐœ
      5. 10.9.5 SWOT ๋ถ„์„
      6. 10.9.6 ํ•ต์‹ฌ ์ „๋žต
    36. 10.10 Mylan NV
      1. 10.10.1 ํšŒ์‚ฌ ๊ฐœ์š”
      2. 10.10.2 ์žฌ๋ฌด ๊ฐœ์š”
      3. 10.10.3 ์ œํ’ˆ ์ œ๊ณต
      4. 10.10.4 ์ฃผ์š” ๊ฐœ๋ฐœ
      5. 10.10.5 SWOT ๋ถ„์„
      6. 10.10.6 ์ฃผ์š” ์ „๋žต
    37. 10.11 ๊ธฐํƒ€
    38. 11.1 ์ฐธ๊ณ ๋ฌธํ—Œ
    39. 11.2 ๊ด€๋ จ ๋ณด๊ณ ์„œ
Case Study Cover Image
์‚ฌ๋ก€ ์—ฐ๊ตฌ

Aerospace & Defense